Molecular Templates, Inc.

Stocks

MTEM

US6085502085

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 16:47:46 21/07/2025 BST			5-day change	1st Jan Change
0.000100 ^USD	-.--%		-.--%	-

18/07/25	Molecular Templates, Inc. Emerged from Bankruptcy	CI
02/07/25	Second Revised Combined Joint Reorganization Plan and Disclosure Statement Approved for Molecular Templates, Inc.	CI

Motion for Joint Administration Approved for Molecular Templates, Inc.

Published on 04/22/2025 at 05:00 am BST

S&P Capital IQ

Add MarketScreener to your sources

MOLECULAR TEMPLATES, INC.

-.--%

The US Bankruptcy Court granted an order for the joint administration of the Chapter 11 bankruptcy cases of Molecular Templates, Inc. and its affiliate on April 22, 2025. The affiliate includes Molecular Templates OpCo, Inc. The cases would be jointly administered for administrative and procedural purposes. Molecular Templates, Inc. has been designated as the lead debtor.

Add MarketScreener to your sources

Latest news about Molecular Templates, Inc.

18/07/25	Molecular Templates, Inc. Emerged from Bankruptcy	CI
02/07/25	Second Revised Combined Joint Reorganization Plan and Disclosure Statement Approved for Molecular Templates, Inc.	CI
27/05/25	Combined Revised JOint Reorganization Plan and Disclosure Statement on Interim Basis Approved for Molecular Templates, Inc.	CI
23/05/25	Final DIP Financing Approved for Molecular Templates, Inc.	CI
13/05/25	Molecular Templates, Inc. announced that it expects to receive $250 million in funding	CI
28/04/25	Interim DIP Financing Approved for Molecular Templates, Inc.	CI
22/04/25	Motion for Joint Administration Approved for Molecular Templates, Inc.	CI
21/04/25	Combined Joint Reorganization Plan and Disclosure Statement Filed by Molecular Templates, Inc.	CI
21/04/25	Motion for Joint Administration Filed by Molecular Templates, Inc.	CI
20/04/25	Molecular Templates, Inc. Filed for Bankruptcy	CI
26/02/25	Molecular Templates, Inc. and Molecular Templates OpCo, Inc. Enter into Loan and Security Agreement ? Bridge Loan	CI
29/12/24	Molecular Templates, Inc.(NasdaqCM:MTEM) dropped from S&P TMI Index	CI
24/12/24	Molecular Templates, Inc.(OTCPK:MTEM) dropped from NASDAQ Composite Index	CI
20/12/24	Wall Street Set to Open Lower Friday; Key Inflation Data Lower Than Expected	MT
20/12/24	Investors Await Key Inflation Data as US Futures Decline in Friday's Premarket	MT

Chart Molecular Templates, Inc.

Duration

Period

MTEM: Dynamic Chart

Company Profile

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics. The Companyâ€™s proprietary drug platform technology, known as engineered toxin bodies (ETBs), leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer. Its product pipeline includes MT-6402, MT-8421 and MT-0169. MT-6402 is an ETB consisting of a single chain variable fragments (scFv), with affinity for PD-L1, fused to the enzymatically active de-immunized SLTA and a HLA-A*02 class I antigen derived from the human cytomegalovirus (HCMV) pp65 protein. MT-8421, its ETB targeting CTLA-4, along with MT-6402. MT-0169 is designed to destroy CD38+ tumour cells through internalization of CD38 and cell destruction via a novel mechanism of action (enzymatic ribosomal destruction and immunogenic cell death).

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data